

## T-CELL LYMPHOMAS

*P. Ghione, New York, NY (USA), et al.*

### [RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA \(BIA-ALCL\) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS.](#)

**Authors Conclusion from the abstract:** This study, evaluating the risk of women with textured breast implants from a prospective database with long-term follow-up, demonstrated that the incidence rate of BIA-ALCL may be higher than previously reported. These results can help inform implant choice for women undergoing breast reconstruction.

*M. Lopez-Parra, Salamanca (Spain), et al.*

### [AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY](#)

**Authors Conclusion from the abstract:** Our results indicate that ASCT in 1st CR improves the survival of patients with PTCL other than ALK+ anaplastic large-cell lymphoma. These results should be confirmed in a prospective randomized study. A propensity score matching analysis is planned.

*O. Tournilhac, Clermont-Ferrand (France), et al.*

### [FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY](#)

**Authors Conclusion from the abstract:** AlloSCT or autoSCT given to consolidate response in pts with

PTCL showed no significant survival differences. While exerting a strong GvL-effect alloSCT resulted in substantial TRM. For younger pts with PTCL autoSCT remains the preferred consolidation, in particular, because pts relapsing after autoSCT can be successfully salvaged with alloSCT.

*S. Qi, Beijing (China), et al.*

[TREATMENT BENEFIT ASSOCIATING WITH NON- ANTHRACYCLINE CHEMOTHERAPY IN EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE](#)

**Authors Conclusion from the abstract:** Non-ANT chemotherapy constituted the mainstay of chemotherapy in ENKL treatment. The application of non-ANT chemotherapy associated improved response and survival comparing to ANT chemotherapy.

*R. Tao, Shanghai (China), et al.*

[SINTILIMAB FOR RELAPSED/REFRACTORY \(R/R\) EXTRANODAL NK/T CELL LYMPHOMA \(ENKTL\): A MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL \(ORIENT-4\)](#)

**Authors Conclusion from the abstract:** ORIENT-4 is the first multicenter and prospective study validating efficacy of PD-1 antibody in ENKTL and with results. Sintilimab is effective and well tolerated in r/r ENKTL and could be a promising treatment option for these patients. Early disease progression observed by PET scan in this study could be pseudo-progression as it did not correlate with poor outcome, which warrants further investigation. Clinical trial information: NCT03228836